Intercept Pharmaceuticals (Nasdaq:ICPT) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ICPT Panoramica delle azioni

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.

Informazioni sull'azienda

ICPT analisi fondamentale
Punteggio fiocco di neve
Valutazione	5/6
Crescita futura	4/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Negoziato a 53.1% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 42.37% all'anno

Gli utili sono cresciuti del 22.4% all'anno negli ultimi 5 anni

Negoziato a un buon valore rispetto ai pari e al settore

Analisi del rischio

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Intercept Pharmaceuticals, Inc. Concorrenti

4D Molecular Therapeutics

NasdaqGS:FDMT

US$764.5m

Ironwood Pharmaceuticals

NasdaqGS:IRWD

US$760.4m

Gyre Therapeutics

NasdaqCM:GYRE

US$1.0b

MiMedx Group

NasdaqCM:MDXG

US$961.6m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Intercept Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$19.00
Massimo di 52 settimane	US$21.86
Minimo di 52 settimane	US$8.82
Beta	0.88
1Variazione di 1 mese	1.99%
Variazione a 3 mesi	81.30%
Variazione di 1 anno	19.12%
3Variazione a 3 anni	-50.68%
Variazione a 5 anni	-81.17%
Variazione dall'IPO	-2.06%

Notizie e aggiornamenti recenti

Recent updates

Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Jun 08

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Apr 11

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Dec 20

Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

Sep 20

Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

May 10

Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH

Mar 05

Intercept names Andrew Saik as chief financial officer

Jun 07

Intercept Pharmaceuticals slides as FDA restricts Ocaliva use

May 26

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are Analysts Optimistic?

May 11

Rendimenti per gli azionisti

	ICPT	US Biotechs	US Mercato
7D	0.1%	3.5%	3.1%
1Y	19.1%	14.9%	25.4%

Ritorno vs Industria: ICPT ha superato il US Biotechs che ha restituito 15.7 % nell'ultimo anno.

Rendimento vs Mercato: ICPT ha superato il mercato US che ha restituito 25.6 % nell'ultimo anno.

Volatilità dei prezzi

Is ICPT's price volatile compared to industry and market?
ICPT volatility
ICPT Average Weekly Movement	22.8%
Biotechs Industry Average Movement	10.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.2%

Prezzo delle azioni stabile: Il prezzo delle azioni di ICPT è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di ICPT è aumentata da 15% a 23% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2002	341	Jerry Durso	www.interceptpharma.com

Intercept Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Intercept Pharmaceuticals con la sua capitalizzazione di mercato?
ICPT statistiche fondamentali
Capitalizzazione di mercato	US$794.69m
Guadagni(TTM)	-US$57.47m
Ricavi(TTM)	US$317.68m

2.5x

Rapporto P/S

-13.8x

Rapporto P/E

ICPT è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ICPT Conto economico (TTM)
Ricavi	US$317.68m
Costo del fatturato	US$632.00k
Profitto lordo	US$317.05m
Altre spese	US$374.52m
Guadagni	-US$57.47m

Ultimi guadagni dichiarati

Sep 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.37
Margine lordo	99.80%
Margine di profitto netto	-18.09%
Rapporto debito/patrimonio netto	311.6%

Come si è comportato ICPT nel lungo periodo?

Vedi performance storica e confronto

ICPT Panoramica delle azioni

Premi

Analisi del rischio

Intercept Pharmaceuticals, Inc. Concorrenti

NasdaqGS:FDMT

US$764.5m

NasdaqGS:IRWD

US$760.4m

NasdaqCM:GYRE

US$1.0b

NasdaqCM:MDXG

US$961.6m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Recent updates

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Third quarter 2023 earnings: EPS exceeds analyst expectations

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Now 20% undervalued after recent price drop

Now 22% undervalued after recent price drop

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Price target decreased by 24% to US$15.08

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Price target decreased by 14% to US$21.00

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Price target increased by 9.9% to US$24.00

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 8.2% to US$20.85

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Consensus forecasts updated

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Consensus forecasts updated

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Price target decreased to US$24.00

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

Intercept cuts debt further with deal to exchange convertible notes

Intercept reduces debt with repurchases of $327.9M convertible notes

Intercept Pharmaceuticals: Too Risky To Buy At This Stage

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Intercept Pharma Q2 2022 Earnings Preview

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Consensus forecasts updated

Forecast breakeven date moved forward to 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept to resubmit for FDA approval of NASH candidate after new analysis

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Intercept: Increase Of Ocaliva Sales And A Few Catalysts

Consensus estimates of losses per share improve by 93%

Forecast breakeven date moved forward to 2022

Intercept Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis